"Naphthyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D009287
|
| MeSH Number(s) |
D03.633.100.612
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naphthyridines".
Below are MeSH descriptors whose meaning is more specific than "Naphthyridines".
This graph shows the total number of publications written about "Naphthyridines" by people in this website by year, and whether "Naphthyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 4 | 4 |
| 2024 | 2 | 0 | 2 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naphthyridines" by people in Profiles.
-
Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR). Cardiovasc Diabetol. 2025 Dec 05; 24(1):454.
-
Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis. Kidney Int. 2025 Jul; 108(1):136-144.
-
First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting. J Nephrol. 2024 11; 37(8):2223-2232.
-
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. Trials. 2024 Mar 21; 25(1):203.
-
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Mol Cancer Ther. 2023 06 01; 22(6):717-725.
-
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study. Hepatology. 2023 03 01; 77(3):760-773.
-
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia. Blood Adv. 2023 02 14; 7(3):422-435.
-
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice. J Diabetes Complications. 2023 04; 37(4):108411.
-
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 10 27; 10:CD007004.
-
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.